Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tes...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Cancer
Auteurs principaux: Schmieder, Roberta, Hoffmann, Jens, Becker, Michael, Bhargava, Ajay, Müller, Tina, Kahmann, Nicole, Ellinghaus, Peter, Adams, Robert, Rosenthal, André, Thierauch, Karl-Heinz, Scholz, Arne, Wilhelm, Scott M, Zopf, Dieter
Format: Artigo
Langue:Inglês
Publié: BlackWell Publishing Ltd 2014
Sujets:
Cancer Therapy
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277327/
https://ncbi.nlm.nih.gov/pubmed/24347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.28669
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires